Related references
Note: Only part of the references are listed.Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second-generation antipsychotics (Review)
Octavian Vasiliu
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2023)
Esketamine for treatment-resistant depression: A review of clinical evidence (Review)
Octavian Vasiliu
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2023)
Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives
Evgeny A. Ermakov et al.
FRONTIERS IN PSYCHIATRY (2022)
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Rashmi Shetty et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2022)
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
Kah Kheng Goh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong et al.
ENDOCRINE (2022)
Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus
Yutaka Mizuki et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min et al.
DIABETES THERAPY (2021)
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial
Clare A. Whicher et al.
DIABETES OBESITY & METABOLISM (2021)
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Mark R. Libowitz et al.
FRONTIERS IN PSYCHIATRY (2021)
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Seung Eun Lee et al.
PSYCHIATRY RESEARCH (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis
Yewei Wang et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik et al.
LANCET (2021)
Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis
Ioannis Avgerinos et al.
DIABETES OBESITY & METABOLISM (2020)
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
Richard A. Chudleigh et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)
Dan Siskind et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2020)
GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia
Kyle D. Medak et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2020)
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
Simona Cernea et al.
DRUGS (2020)
Predictive factors in early onset schizophrenia
Magdalena Budisteanu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Dan Siskind et al.
DIABETES OBESITY & METABOLISM (2019)
GLP-1 agonists for metabolic disorders in schizophrenia
Youssef Kouidrat et al.
SCHIZOPHRENIA RESEARCH (2019)
Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis
Erifili Hatziagelaki et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
C. K. Svensson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2019)
Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats
Ilijana Babic et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX)
Dan J. Siskind et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
Pelle L. Ishoy et al.
DIABETES OBESITY & METABOLISM (2017)
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain
Ariel Y. Deutch
JAMA PSYCHIATRY (2017)
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder A Randomized Clinical Trial
Julie R. Larsen et al.
JAMA PSYCHIATRY (2017)
Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes
Jiezhong Chen et al.
FRONTIERS IN NEUROSCIENCE (2017)
Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
Anto P. Rajkumar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia
P. L. Ishoy et al.
ACTA PSYCHIATRICA SCANDINAVICA (2017)
Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control
M. Mar Roca-Rodriguez et al.
ATENCION PRIMARIA (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine
Dan Siskind et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2016)
A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach
Ignacio Neumann et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Karla Mayfield et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Stephen J. Cooper et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span
Ingrid Dieset et al.
SCHIZOPHRENIA BULLETIN (2016)
Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Hannah A. Blair et al.
DRUGS (2015)
Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
Kristy M. Heppner et al.
ENDOCRINOLOGY (2015)
Causes of decreased life expectancy over the life span in bipolar disorder
Lars Vedel Kessing et al.
JOURNAL OF AFFECTIVE DISORDERS (2015)
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Guillermo Umpierrez et al.
DIABETES CARE (2014)
Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
Pelle L. Ishoy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
C. Kapitza et al.
DIABETES OBESITY & METABOLISM (2013)
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
Bjorn H. Ebdrup et al.
BMC MEDICINE (2012)
Beyond PICO: The SPIDER Tool for Qualitative Evidence Synthesis
Alison Cooke et al.
QUALITATIVE HEALTH RESEARCH (2012)
Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations
J. L. Brozek et al.
ALLERGY (2011)
Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London
Chin-Kuo Chang et al.
PLOS ONE (2011)
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model
Heidi N. Boyda et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration
Araba F. Chintoh et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
Kirsten Lykkegaard et al.
SCHIZOPHRENIA RESEARCH (2008)
Share Paper
